How to Get GLP-1 Medications Without Insurance

The retail price of brand-name GLP-1 medications is genuinely prohibitive for most people paying out of pocket. Wegovy lists at around $1,300 per month. Mounjaro and Zepbound aren’t far behind. If your insurance doesn’t cover these medications, or you don’t have insurance at all, that price point ends the conversation before it starts for a lot of patients. But the brand-name retail price isn’t the only number that matters. There are legitimate pathways to GLP-1 treatment that don’t require insurance coverage, and understanding them is worth the time.

Why Insurance Coverage Is Inconsistent

Before getting into alternatives, it helps to understand why so many people are in this situation in the first place. Insurance coverage for obesity medications has historically lagged behind the clinical evidence supporting them. Many employer-sponsored plans carved out weight loss medications as an excluded benefit category years ago, and updating those exclusions requires active decisions by employers and insurers that haven’t always happened.

The result is that two patients with identical clinical profiles can have very different access based entirely on who their employer is or which state they live in. If you’ve already explored your insurance options and hit a wall, the pathways below are where to focus your attention.

For patients who have commercial insurance and want to understand the prior authorization and appeals process before giving up on coverage, does insurance cover Wegovy covers that process in detail.

Option 1: Compounded Semaglutide and Tirzepatide

This is the most significant development in GLP-1 access for uninsured and underinsured patients. Compounded semaglutide and tirzepatide are prepared by licensed compounding pharmacies using the same active pharmaceutical ingredients as brand-name medications, but without the brand-name pricing.

The cost difference is substantial. Where brand-name Wegovy runs over $1,000 per month at retail, compounded semaglutide through a telehealth provider can cost a fraction of that, often in the range of $179 to $400 per month depending on the provider, dose, and program structure.

Compounded medications are legal under federal pharmacy law and are prescribed by licensed providers. They are not FDA-approved as finished drug products the way brand-name medications are, which is a distinction worth understanding, but the active ingredient is the same and compounding pharmacies are regulated by state boards of pharmacy and, in some cases, the FDA.

TrimRx offers compounded semaglutide and compounded tirzepatide through a telehealth model that doesn’t require in-person visits or insurance. You can review current pricing and program details on the compounded semaglutide and compounded tirzepatide product pages.

Option 2: Manufacturer Savings Programs

For patients with commercial insurance that doesn’t cover GLP-1 medications, manufacturer savings cards can reduce out-of-pocket costs meaningfully. These programs are offered directly by Novo Nordisk (for Ozempic and Wegovy) and Eli Lilly (for Mounjaro and Zepbound).

The savings amounts vary and change periodically, but eligible patients with commercial insurance have in some cases paid as little as a few hundred dollars per month or less through these programs.

Important limitations: these savings programs are not available to patients on Medicare, Medicaid, or other government-funded insurance. They also typically require that the patient have some form of commercial insurance, even if that insurance doesn’t cover the medication. Patients with no insurance at all generally don’t qualify.

Checking directly with the manufacturer’s website or asking your pharmacist to run the savings card at the point of sale is the most reliable way to know what you’d actually pay.

Option 3: Telehealth Providers

The telehealth model has changed how patients access GLP-1 medications in meaningful ways. Before telehealth, getting a semaglutide prescription required an in-person visit with a physician, which added time, cost, and a geographical barrier for patients without access to obesity medicine specialists.

Telehealth providers can prescribe GLP-1 medications after an online consultation, often within a few days of a patient completing an intake assessment. For compounded medications specifically, the entire process, from consultation to home delivery, happens without a single in-person appointment.

This matters for cost because telehealth providers typically operate with lower overhead than traditional medical practices, and many offer program pricing that bundles the consultation, prescription, and medication into a single monthly cost. That predictability makes budgeting more straightforward for patients paying out of pocket.

Option 4: GoodRx and Discount Programs for Brand-Name Medications

For patients who specifically want or need a brand-name GLP-1 medication and don’t have coverage, GoodRx and similar pharmacy discount programs can reduce the retail price. The savings are real but limited. GoodRx pricing for Wegovy or Mounjaro typically still runs several hundred dollars per month at minimum, and often significantly more depending on the pharmacy and dose.

Where discount programs are more useful is for patients on Ozempic for a diabetes indication, where pricing is somewhat lower than the dedicated weight loss formulations. For context on what GoodRx pricing looks like for specific medications, GoodRx Ozempic price breaks down the realistic savings.

Discount programs are worth checking but shouldn’t be the first stop for patients focused on affordability. Compounded options through telehealth providers will generally be less expensive for patients without any insurance coverage.

Option 5: Patient Assistance Programs

Both Novo Nordisk and Eli Lilly offer patient assistance programs for qualifying patients who meet income eligibility requirements and don’t have insurance coverage. These programs can provide medications at low or no cost for patients who qualify.

Eligibility requirements vary and the application process takes time, but for patients with limited income who are seeking brand-name medications, it’s worth investigating. Your prescribing provider’s office can often assist with the application process, and information is available directly through each manufacturer’s website.

What You’ll Realistically Pay

Here’s a practical breakdown of what different pathways cost for patients without insurance coverage:

These are approximate ranges and vary by provider, dose, and program. The compounded telehealth pathway is consistently the most accessible for patients paying entirely out of pocket.

Is Compounded GLP-1 as Effective as Brand Name?

This is the question most patients ask when they first encounter compounded options. The active ingredient in compounded semaglutide is the same molecule as in Wegovy and Ozempic. What differs is the manufacturing process, the lack of FDA approval as a finished drug product, and in some formulations, the presence of additional ingredients like B12 or other compounds.

Clinical providers who prescribe both brand-name and compounded GLP-1 medications generally report similar outcomes when the dosing is equivalent. The tirzepatide weight loss results page covers what the research shows about outcomes, which applies broadly to compounded versions at equivalent doses.

Taking the Next Step

Not having insurance coverage for GLP-1 medications is a real barrier, but it’s not an insurmountable one. Compounded semaglutide and tirzepatide through telehealth providers have made these medications accessible to a much broader patient population than was possible even two years ago.

If you’re ready to find out whether you’re a candidate for GLP-1 treatment and want to understand what it would cost through TrimRx, start your assessment to connect with a provider and get a clear picture of your options.

This information is for educational purposes and is not medical advice. Consult with a healthcare provider before starting any medication. Individual results may vary.